Rectal cancer
Conditions
Interventions
intervention group:Oral probiotics (Clostridium butyricum live bacteria capsules, 1260 mg per dose, twice daily) and prebiotics (inulin rich in fructooligosaccharides, 6 g per dose, once daily)
Control group:Placebo of equivalent dosage
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Voluntarily participates in the study and signs the informed consent form; 2.Diagnosed with colorectal cancer through colonoscopy and pathological examination; 3.In generally good health, aged between 18 and 75 years; 4.No evidence of distant metastasis; 5.No severe dysfunction of the heart, lungs, kidneys, or liver prior to surgery; 6.Has completed at least four cycles of neoadjuvant chemotherapy with either the FOLFOX or XELOX regimen.
Exclusion criteria
Exclusion criteria: 1.Use of any antibiotics within one week prior to enrollment; 2.Presence of malignant tumors in other sites or a history of malignancy; 3.Presence of metabolic diseases such as obesity, diabetes, or various liver diseases; 4.Family history of clustered cases; 5.Incomplete clinical data that cannot be retrieved.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of infections within one month after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory markers within 30 days after surgery;Comparison of postoperative adverse events evaluated by Clavien–Dindo classification at 7 and 30 days; | — |
Countries
China
Contacts
Public ContactXiaorong Deng
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed